Bank of New York Mellon
IMDX

Bank of New York Mellon’s Insight Molecular Diagnostics IMDX Stock Holding History

Bank of New York Mellon’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,110
Closed -$9.71K – 4390
2023
Q2 		$9.71K Sell
2,110
-1,045
-33% -$5.26K ﹤0.01% 4342
2023
Q1 		$22.4K Hold
3,155
– – ﹤0.01% 4298
2022
Q4 		$20.3K Sell
3,155
-9
-0.3% -$99 ﹤0.01% 4356
2022
Q3 		$46K Hold
3,164
– – ﹤0.01% 4339
2022
Q2 		$57K Sell
3,164
-7,491
-70% -$170K ﹤0.01% 4327
2022
Q1 		$317K Sell
10,655
-75
-0.7% -$2.4K ﹤0.01% 3986
2021
Q4 		$466K Buy
10,730
+167
+2% +$9.61K ﹤0.01% 3855
2021
Q3 		$752K Buy
10,563
+779
+8% +$71.6K ﹤0.01% 3568
2021
Q2 		$1.12M Buy
9,784
+609
+7% +$59.5K ﹤0.01% 3334
2021
Q1 		$953K Buy
9,175
+806
+10% +$76.5K ﹤0.01% 3359
2020
Q4 		$400K Buy
8,369
+2,494
+42% +$91.5K ﹤0.01% 3721
2020
Q3 		$163K Hold
5,875
– – ﹤0.01% 3886
2020
Q2 		$224K Buy
5,875
+2,483
+73% +$128K ﹤0.01% 3767
2020
Q1 		$167K Buy
3,392
+675
+25% +$33.1K ﹤0.01% 3789
2019
Q4 		$122K Hold
2,717
– – ﹤0.01% 4000
2019
Q3 		$114K Sell
2,717
-1,169
-30% -$45.9K ﹤0.01% 4003
2019
Q2 		$194K Buy
3,886
+2,912
+299% +$242K ﹤0.01% 3931
2019
Q1 		$77K Buy
+974
New +$62.8K ﹤0.01% 4041
2018
Q1 		– Sell
-839
Closed -$78K – 4387
2017
Q4 		$78K Sell
839
-14
-2% -$1.58K ﹤0.01% 4138
2017
Q3 		$129K Sell
853
-1
-0.1% -$105 ﹤0.01% 3962
2017
Q2 		$89K Buy
854
+325
+61% +$37K ﹤0.01% 4049
2017
Q1 		$63K Buy
+529
New +$61.1K ﹤0.01% 4111

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon's IMDX Position: Q3 2023 in Review

Bank of New York Mellon sold out of Insight Molecular Diagnostics (IMDX) in Q3 2023, closing a stake of 2,110 shares — an estimated $9.71K sold.

Bank of New York Mellon first reported a position in IMDX in Q1 2017 and held it in 22 quarters. The position peaked at $1.12M in Q2 2021. 30 funds tracked by Wall St. Rank hold IMDX as of Q3 2023.

  • Bank of New York Mellon reported no remaining Insight Molecular Diagnostics position as of Q3 2023 after selling out during the quarter.
  • Bank of New York Mellon sold 2,110 Insight Molecular Diagnostics shares in Q3 2023, an estimated $9.71K.
  • Bank of New York Mellon first reported a position in Insight Molecular Diagnostics in Q1 2017 and held it in 22 quarters.
  • Bank of New York Mellon's Insight Molecular Diagnostics position peaked at $1.12M in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2023.

Based on Bank of New York Mellon's 13F filing for Q3 2023, filed 24 Oct 2023.